Senate's Bipartisan Rx Pricing Probe Seeks Documents Regarding FDA Regs

Probe launched by the Senate Aging panel asks four manufacturers – Valeant, Turing, Retrophin and Rodelis – for documents pertaining to pricing their products, but also wants to know how they may have analyzed FDA regs to help them avoid competition.

A Senate committee has turned what was primarily a Democrat campaign against high drug prices into a bipartisan concern and is also pulling FDA regulations into the discussion.

The Special Committee on Aging penned letters to four drug manufacturers – Valeant Pharmaceuticals International Inc. (Valeant letter), Turing Pharmaceuticals AG(Turing letter), Retrophin Inc. (

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America